4.7 Article

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA

出版社

SPRINGER
DOI: 10.1007/s00259-017-3728-y

关键词

Neuroendocrine tumours; Neuroendocrine neoplasms; Pet/Ct; Ga-68-DOTATATE; Ga-68-DOTATOC; Ga-68-DOTANOC; F-18-DOPA; F-18-FDG; Thyroid medullary cancer; Pheochromoacytoma; Paraganglioma; Foregut-NET; Midgut-NET; Hindgut-NET; Hyperinsulism in infants

资金

  1. Novo Nordisk Fonden [NNF15OC0017912] Funding Source: researchfish
  2. The Danish Cancer Society [R146-A9491] Funding Source: researchfish

向作者/读者索取更多资源

Purpose & Methods Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using Ga-68-DOTA-conjugated peptides, as well as F-18-DOPA imaging for various neuroendocrine neoplasms. Results & Conclusion The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with Ga-68-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据